Artiva’s Off-the-Shelf Answer to Autoimmune CAR-T
The excitement in autoimmune disease right now runs through cell therapy. Researchers have shown that clearing a patient’s B cells can drive long remissions in lupus and related conditions, effectively resetting the immune system. The catch is cost and complexity. Autologous CAR-T is built one patient at a time, requires hospital monitoring, and carries serious side effects. Artiva Biotherapeutics (Nasdaq: ARTV) is testing a different route.
Its lead candidate, AlloNK, is an allogeneic, off-the-shelf natural killer cell therapy given alongside rituximab. Rather than engineering a patient’s own T cells, it uses donor-derived NK cells to deepen the B-cell depletion that rituximab begins. The pitch is CAR-T-like depletion delivered in an outpatient setting, at a fraction of the manufacturing cost.
Strong signal, thin sample
At EULAR 2026 in June, Artiva presented data across refractory rheumatoid arthritis, Sjogren disease, and systemic sclerosis. In its company-sponsored Phase 2a basket trial, five of seven refractory RA patients with six months of follow-up reached an ACR50 response, the 71% rate the company highlighted. Across pooled trials, responses deepened over time, and no patient had lost response as of the April 3 cutoff. Translational data showed deep, consistent B-cell depletion, with reconstitution favoring naive B cells, the reset the company is chasing.
The caveat is scale. These are single-digit and low-double-digit patient counts pooled across separate trials, and Artiva itself notes that cross-trial comparisons are inherently limited. A clean safety profile, with no cytokine release syndrome or neurotoxicity across 55 patients, supports the outpatient claim but rests on the same early sample.
The setup for a real test
The FDA granted AlloNK RMAT designation in refractory RA, which brings earlier agency interaction and supports the registrational path. Artiva plans a single Phase 3 trial of about 150 refractory RA patients, randomized against rituximab alone, with a readout the company expects in the second half of 2028 and a filing targeted for 2029. A May financing left the company saying its runway now extends into 2029, enough, on its telling, to reach that readout.
For now the mechanism is the bet and the Phase 3 is the proof. Artiva has a differentiated approach, a funded plan, and early data that reads well. Whether an off-the-shelf therapy can match bespoke CAR-T in a controlled trial is the question the next two years answer.
This is not investment advice. Clinical-stage biotech carries binary trial risk, and early results may not hold in larger studies. Do your own diligence.
